gemcitabine has been researched along with Nasopharyngeal Carcinoma in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 30 (54.55) | 24.3611 |
| 2020's | 25 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Chen, Y; He, QM; He, SW; Huang, SY; Li, XM; Li, YQ; Liu, N; Luo, WJ; Ma, J; Yang, XJ; Zhang, Y; Zhao, Y | 1 |
| Chen, QY; Du, CC; Guo, SS; Liu, LT; Liu, T; Mai, HQ; Yang, ZC | 1 |
| Du, C; Hu, C; Jiang, J; Kong, F; Lv, Y; Ni, M; Ying, H; Zhai, R | 1 |
| Chen, Q; Li, S | 1 |
| Chen, L; Jiang, N; Li, JY; Li, WF; Li, XM; Li, YQ; Liu, N; Ma, J; Mao, YP; Tang, LL; Zhang, XM; Zhang, Y; Zhou, GQ | 1 |
| Cai, MB; Li, ZM; Nie, YH; Tan, YR; Yang, Q; Zhu, HB | 1 |
| An, HJ; Cho, S; Hong, MH; Jung, HA; Keam, B; Lee, KW; Lim, J; Ock, CY; Park, KU; Park, WY; Pereira, S; Yun, T | 1 |
| Chen, MY; Ding, X; Duan, CY; Gu, CM; Hua, YJ; Huang, PY; Liu, YL; Liu, YP; Ouyang, YF; Wang, X; Wang, ZQ; Xu, HS; You, R; Zhang, MX; Zhang, WJ; Zou, X | 1 |
| Chen, Q; Li, S; Shen, L | 1 |
| Chen, YP; Guan, JL; Guo, R; He, QM; He, SW; Huang, ZL; Jin, X; Kuang, DM; Li, GB; Li, JY; Li, WF; Li, XM; Liang, XY; Liu, N; Lv, J; Ma, J; Mao, YP; Shen, JY; Sun, R; Sun, Y; Tang, LL; Wang, SQ; Wei, C; Wei, Y; Xiong, KX; Yin, JH; Zhang, CJ; Zhang, Y; Zheng, YH; Zhou, GQ; Zhou, WW | 1 |
| Chen, D; Chen, QY; Chen, X; Chen, Y; Feng, H; He, X; Hsieh, CY; Hu, C; Jiang, Y; Jin, F; Jing, S; Keegan, P; Li, J; Li, P; Li, Q; Liao, W; Lim, WT; Lin, X; Liu, YC; Lu, Y; Luo, X; Mai, HQ; Pan, J; Qu, S; Samol, J; Shi, Y; Tang, X; Wang, HM; Wang, S; Wang, X; Wen, J; Xu, R; Xu, RH; Yang, K; Yang, MH; Yao, S; Yen, CJ; Yuan, X | 1 |
| Ai, P; Chen, N; Duan, B; Li, Y; Shi, H; Tian, J; Zhu, J | 1 |
| Jin, C; Wen, F; Xu, T; Zhan, M; Zheng, H | 1 |
| Li, G; Li, H; Peng, C; Shi, L; Zhou, C | 1 |
| Huang, J; Li, Q; Liao, W; Wu, Q; Zhang, N; Zhang, P | 1 |
| Li, C; Luo, S; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L | 1 |
| Luttke, M; Marschner, S; Späth, R; Walter, F | 1 |
| Chen, WP; Huang, YM; Li, SL; Lu, L; Qi, CH; Qiao, SQ | 1 |
| Chan, GHJ; Chong, SM; Chong, WQ; Goh, BC; Goh, RM; Ho, FCH; Huang, Y; Jeyasekharan, AD; Kong, LR; Kumarakulasinghe, NB; Lau, JA; Lee, SC; Lim, CM; Lim, YC; Loh, KS; Loh, WS; Sinha, AK; Soo, RA; Soon, YY; Sundar, R; Tai, BC; Tan, CS; Tay, JK; Wang, L; Wong, AL; Yadav, K | 1 |
| Chan, SK; Chan, SY; Choi, HC; Kwong, DL; Lam, KO; Lee, AW; Lee, VH; Leung, TW; Luk, MY; Tong, CC | 1 |
| Chen, HB; Chen, SW; Fei, Q; He, X; Xu, JJ; Zhang, CM | 1 |
| Cui, J; Pan, LX; Tan, HF; Xiao, Z; Zhang, LL | 1 |
| Jia, Z; Tang, M; Zhang, J | 1 |
| Chen, D; Chen, QY; Chen, X; Chen, Y; Feng, H; He, X; Hsieh, CY; Hu, C; Jiang, Y; Jin, F; Jing, S; Keegan, P; Li, J; Li, P; Li, Q; Liao, W; Lim, WT; Lin, X; Liu, YC; Liu, Z; Lu, Y; Mai, HQ; Pan, J; Qu, S; Samol, J; Shi, YR; Wang, HM; Wen, J; Xu, R; Xu, RH; Yang, K; Yang, MH; Yao, S; Yen, CJ; Yuan, X | 1 |
| Cao, JX; Lu, FT; Luo, F; Luo, M; Luo, QY; Ma, WJ; Pan, WT; Qiu, MZ; Xia, ZF; Yang, DJ; Zeng, KM; Zhang, L; Zhang, ZH; Zhao, HY; Zhou, T | 1 |
| Kang, W; Li, Y; Liao, J; Xiao, L | 1 |
| Fong, KW; Hussain, A; Ong, WS; Sommat, K; Soong, YL; Tan, T; Wee, J | 1 |
| de Greeuw, I; Eersels, JLH; Greijer, AE; Middeldorp, JM; Molthoff, CFM; Novalić, Z; Verkuijlen, SAWM; Verlaan, M | 1 |
| He, X; Hu, C; Ou, D; Wu, M | 1 |
| Hu, C; Li, Y; Lu, X; Qian, W; Xu, T | 1 |
| Kwong, DLW | 1 |
| Li, B; Liao, W; Wen, H; Xu, P; Zhang, S; Zheng, L | 1 |
| Fan, JF; Jiang, W; Kong, XY; Liao, SF; Lu, JX; Mi, JL; Qin, XL; Tang, HY; Xu, QL; Yao, DC; Yu, XW; Zhang, J; Zhang, RJ | 1 |
| Chen, L; Chen, YP; Cheng, ZB; Chua, MLK; Du, XJ; Guo, R; Guo, Y; Han, F; Hu, GQ; Hu, WH; Huang, J; Jin, F; Li, JG; Li, L; Li, WF; Li, YH; Li, YQ; Liang, SQ; Liu, N; Liu, QD; Liu, X; Long, GX; Long, JH; Lv, JW; Ma, J; Mao, YP; Mo, HY; Shi, M; Su, QF; Sun, R; Sun, Y; Tang, LL; Tian, Y; Wang, SY; Wang, XC; Xiao, Y; Xie, FY; Xu, C; Yang, KY; Zang, J; Zhang, N; Zhang, Y; Zheng, BM; Zhou, GQ; Zhu, XD; Zou, L | 1 |
| Chen, X; Jiang, J; Liang, W; Wan, N; Yang, Y; Zhang, L; Zhang, T | 1 |
| Sidaway, P | 1 |
| Ma, J; Sun, Y; Zhang, Y | 1 |
| Hussain, R; Iqbal, H; Jamshed, A | 1 |
| Chen, XZ; Jin, T; Li, B | 1 |
| Ang, MK; Cheah, SL; Fong, KW; Lim, WT; Ng, QS; Ong, WS; Quah, D; Soo, KC; Soong, YL; Tan, D; Tan, SH; Tan, T; Wee, J; Yip, C | 1 |
| de Boer, JP; Greijer, AE; Huitema, AD; Juwana, H; Middeldorp, JM; Novalić, Z; Stoker, SD; Tan, IB; Verkuijlen, SA; Wildeman, MA | 1 |
| Chang, YF; Chen, SY; Hsiao, CH; Hsieh, JC; Hsieh, RK; Hsu, CL; Lee, KD; Lu, CH; Ng, SH; Shiau, CY; Wang, CH; Wang, HM; Yeh, KH | 1 |
| Gu, MF; Li, JJ; Li, Y; Li, YQ; Liu, LZ; Pan, K; Shen, WX; Xia, JC; Zhang, H | 1 |
| Barreca, GS; Costa, C; Donato, G; Focà, A; Giancotti, A; La Boria, A; Liberto, MC; Pisani, V; Roveda, L; Strazzulla, A; Torti, C; Tucci, L; Zicca, E | 1 |
| Chang, KP; Chang, YS; Fan, HC; Hsieh, CH; Hsu, CL; Huang, Y; Huang, YC; Kuo, YC; Lee, LY; Li, HP; Lin, AC; Lin, TL; Lui, KW; Wang, HM | 1 |
| Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S | 1 |
| Fang, W; Tian, Y; Xue, C; Zhan, J; Zhang, J; Zhang, L; Zhao, Y | 1 |
| Cheah, SL; Chua, ML; Fong, KW; Kusumawidjaja, G; Shwe, MT; Soong, YL; Tan, SH; Tan, TW; Wee, JT | 1 |
| Hong, S; Zhang, L | 1 |
| Jiang, W; Luo, S; Pan, H; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L; Zhou, Y | 1 |
| Feng, B; Fu, JT; Hu, Y; Shi, D; Shi, Z | 1 |
| He, X; Hu, C; Liu, T; Ou, D; Xiayun, H; Ying, H; Zhu, G | 1 |
| Gu, MF; He, LJ; Li, JJ; Liu, LZ; Luo, GY; Xu, GL; Yan, CX; Yuan, WX; Zhang, HM; Zhang, R | 1 |
| Cai, XY; Cai, YC; Cao, Y; Hu, WH; Jiang, WQ; Jin, Y; Shi, YX; Xia, XY; Zhang, WD | 1 |
| de Boer, JP; Greijer, AE; Huitema, AD; Juwana, H; Middeldorp, JM; Novalic, Z; Tan, IB; Verkuijlen, SA; Wildeman, MA | 1 |
4 review(s) available for gemcitabine and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Case-Control Studies; Chemoradiotherapy; China; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Observational Studies as Topic; Progression-Free Survival; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2021 |
The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Nasopharyngeal carcinoma: review of the literature with a focus on therapeutical implications.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Valproic Acid | 2015 |
18 trial(s) available for gemcitabine and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Topics: Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; B7-H1 Antigen; Chromatin; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nivolumab; Programmed Cell Death 1 Receptor | 2022 |
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Gemcitabine; Humans; Internationality; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; United States | 2023 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Markov Chains; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Quality-Adjusted Life Years | 2020 |
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Sunitinib | 2020 |
Efficacy and safety of two different adjuvant chemotherapy regimens in combination with concurrent chemoradiotherapy in treating patients with advanced nasopharyngeal carcinoma: A protocol for randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic | 2021 |
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Progression-Free Survival | 2021 |
Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Hypothyroidism; Incidence; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Pituitary Gland; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Thyroid Gland; Time Factors | 2017 |
Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Young Adult | 2017 |
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Prospective Studies; Young Adult | 2019 |
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Leukopenia; Male; Middle Aged; Nasopharyngeal Carcinoma; Survival Analysis; Young Adult | 2019 |
A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Endostatins; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Recombinant Proteins; Treatment Outcome | 2013 |
Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Patient Compliance; Quality of Life; Radiation-Sensitizing Agents | 2015 |
Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.
Topics: Adult; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; DNA, Viral; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunoglobulin A; Immunoglobulin G; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; T-Lymphocytes; Valproic Acid; Virus Latency | 2015 |
Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial.
Topics: Adult; Aged; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taiwan; Treatment Outcome | 2015 |
Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma; Cisplatin; Cytokine-Induced Killer Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2015 |
Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate | 2016 |
Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; China; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome | 2012 |
Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Young Adult | 2013 |
33 other study(ies) available for gemcitabine and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Management of first-line palliative chemotherapy for post-treatment metastasis after gemcitabine plus cisplatin induction chemotherapy: Gemcitabine plus cisplatin and non-gemcitabine plus cisplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis.
Topics: Carcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids; Treatment Outcome | 2022 |
Gemcitabine Versus Docetaxel Plus Cisplatin as Induction Chemotherapy in Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies | 2022 |
The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma.
Topics: Cisplatin; Deoxycytidine; Gemcitabine; HLA-DR Antigens; Humans; Induction Chemotherapy; Interleukin-2; Interleukin-5; Interleukin-6; Interleukin-8; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Quality of Life; Retrospective Studies; Treatment Outcome | 2022 |
Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Circulating Tumor DNA; Clinical Trials as Topic; Deoxycytidine; Endothelial Growth Factors; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Necrosis; Neoplasm Recurrence, Local; Pyridines | 2022 |
Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma.
Topics: Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Tumor Burden | 2023 |
The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Tumor Microenvironment | 2023 |
Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2019 |
Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis.
Topics: Adult; Aged; Angiography, Digital Subtraction; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Hepatic Artery; Humans; Infusion Pumps; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Treatment Outcome; Vascular Access Devices | 2020 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Markov Chains; Middle Aged; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Randomized Controlled Trials as Topic; Young Adult | 2020 |
Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome | 2020 |
[Induction Chemotherapy with Gemcitabine and Cisplatin followed by Radiochemotherapy in locally advanced Nasopharyngeal Carcinoma].
Topics: Chemoradiotherapy; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2020 |
Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Taxoids; Time Factors | 2020 |
Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinom
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Progression-Free Survival; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; bcl-X Protein; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Janus Kinase 2; Models, Biological; Myeloid Cell Leukemia Sequence 1 Protein; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Piperidines; Signal Transduction; Small Molecule Libraries; STAT3 Transcription Factor | 2021 |
Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Topics: Animals; Antiviral Agents; Carcinoma; Deoxycytidine; Disease Models, Animal; DNA, Viral; Epstein-Barr Virus Infections; Ganciclovir; Gemcitabine; Herpesvirus 4, Human; Humans; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Tumor Cells, Cultured; Valproic Acid; Viral Load; Virus Activation | 2017 |
Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Diseases; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, High-Energy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Ulcer | 2018 |
Camrelizumab for nasopharyngeal carcinoma: a new hope?
Topics: Carcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2018 |
Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Tumor Burden | 2018 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Humans; Male; Markov Chains; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Induction chemotherapy improves efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2019 |
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Topics: Animals; Anticonvulsants; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Carcinoma; Cell Proliferation; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Epstein-Barr Virus Infections; Ganciclovir; Gemcitabine; Gene Expression Profiling; Herpesvirus 4, Human; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Oncolytic Virotherapy; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Valproic Acid; Viral Load; Virus Activation; Xenograft Model Antitumor Assays | 2015 |
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Ifosfamide; Induction Chemotherapy; Kaplan-Meier Estimate; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neutropenia; Platinum; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure | 2015 |
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship | 2016 |
Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA, Viral; Epstein-Barr Virus Infections; Female; Fluorouracil; Gemcitabine; Herpesvirus 4, Human; Humans; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutrophils; Prognosis; Proportional Hazards Models; Radiotherapy; Randomized Controlled Trials as Topic; Singapore; Survival Rate | 2016 |
Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2017 |
Clinical efficacy and safety of gemcitabine plus nedaplatin in the treatment of advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Case-Control Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Treatment Outcome | 2016 |
Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Retrospective Studies | 2012 |
Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.
Topics: Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunoglobulin G; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Treatment Outcome; Valproic Acid; Viral Load; Virus Activation | 2012 |